CIK细胞联合二线化疗治疗晚期肺癌的临床效果观察  

Observation of curative effect of cytokine-induced killer cells bio-therapy combined with second-line chemotherapy in the treatment of advanced lung cancer

作　　者：曾辉[1,2] 宋文玲[1,2] 韩蓉[1,2] 张曼[1,2] 程丽萍[1,2] 杨媛[1,2] 

机构地区：[1]武汉市黄陂区人民医院 [2]江汉大学附属第三医院肿瘤三科,湖北武汉432200

出　　处：《临床肺科杂志》2015年第10期1787-1790,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察CIK（Cytokine-induced—killer）细胞联合二线化疗对一线化疗治疗失败的晚期肺癌患者的临床治疗效果。方法将2012年10月一2014年2月，40例经一线化疗无效的晚期肺癌患者随机分为两组：CIK细胞联合二线化疗药物组（n=21）和单用二线化疗药物组（n=19）。对两组的疾病控制率、缓解率、无疾病进展期和生存期进行观察比较。结果CIK细胞联合化疗组的ORR（Objective responserate，客观缓解率）和DCR（Diseasecontrolrate，疾病控制率）分别达到33．3％和81．0％，而单用化疗药物治疗组ORR和DCR分别为15．8％和63．2％（PORR=O．361，PDCR=0．366）。CIK细胞联合化疗组的PFS（中位无疾病进展期）和OS（中位总生存期）分别为5．5个月（95％C13．71-7．29个月）及13．8个月（95％Cl10．75～16．85个月），相比而言，单用化疗药物组则分别为3．0个月（95％CI2．68—3．32个月）及9．5个月（95％CI8．38-10．62个月）。联合治疗组的患者有着明显更长的PFS和OS（PPFS=0．024，POS=0．042）。结论CIK细胞联合二线化疗药物治疗一线化疗失败的晚期肺癌患者比单用二线化疗药物治疗可明显延长患者的PFS和平均存活时间。Objective To investigate the efficacy of cytokine-induced killer （CIK） immune cells combined with second-line chemotherapy in treating advanced lung cancer patients after failure of first-line chemotherapy. Methods 40 advanced lung cancer patients from October 2012 and February 2014, who failed at the first-line chem- otherapy, were randomly divided into two groups. The observation group was given CIK immune cells transfusion combined with second-line chemotherapy （ CIK ＋ Chemotherapy）, and the control group was given the second-line chemotherapy alone. The objective response rate （ORR）, disease control rate （DCR）, time to progression and sur- vival time were compared between the two groups. Results The ORR and DCR were 33.3% and 81.0 % respec- tively in the observation group, and 15.8% and 63.2% in the control group （PoRR =0. 361, PDC~ =0. 366） respec- tively. The time to disease progression and median survival time was 5.5 months （95% CI 3.71-7. 29 months） and 13.8 months （ 95% CI 10.75-16. 85 months ） in the observation group, and 3.0 months （ 95% CI 2. 68-3.32 months） and 9. 5 months （95% CI 8.38-10. 62 months） in the control group respectively. In addition, the observa- tion group had significantly longer PFS and OS （ PPFS = 0. 024, Pos = 0. 042）. Conclusion CIK cells combined with second-line chemotherapy can significantly improve and prolong PFS and median survival compared with second-line chemotherapy drugs alone in the treatment of patients with advanced lung cancer after first-line chemotherapy failure.

关 键 词：细胞因子诱导的杀伤细胞 晚期肺癌 二线化疗 疗效 

分 类 号：R734.2[医药卫生—肿瘤]